Relmada Therapeutics

RLMD46

Penny Stock

$3.40arrow_drop_up3.97%$0.13

Penny Stock

RLMD46

$3.40

arrow_drop_up3.97%$0.13

Penny Stock

Performance History

Key Stats
Open	$3.24
Prev. Close	$3.27
EPS	-2.87
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$95.95M
PE Ratio	-

	LOW	HIGH
Day Range	3.19	3.49
52 Week Range	1.88	7.22

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.87

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Relmada Therapeutics (RLMD)

Relmada Therapeutics Inc. (ticker symbol RLMD) is a pharmaceutical company specializing in the development and commercialization of novel therapies for the treatment of various central nervous system (CNS) disorders. With a focus on precision medicine, Relmada aims to deliver innovative solutions that improve the lives of patients suffering from conditions such as chronic pain, depression, and other CNS disorders.

Founded in 2004, Relmada has a diverse pipeline of product candidates that target different neurological indications. The company's lead compound is REL-1017 (dextromethadone), a novel N-methyl-D-aspartate (NMDA) receptor antagonist currently being evaluated in Phase 3 clinical trials for the treatment of major depressive disorder (MDD). REL-1017 has shown promising results in early-stage studies and has the potential to address the limitations of current antidepressant medications, which often have delayed onset of action and limited efficacy in certain patient populations.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
Headquarters: Coral Gables
Employees: 14
Exchange: NASDAQ

Keep an eye on Relmada Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Relmada Therapeutics 's (RLMD) price per share?

The current price per share for Relmada Therapeutics (RLMD) is $3.4. The stock has seen a price change of $0.13 recently, indicating a 3.98% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Relmada Therapeutics (RLMD)?

For Relmada Therapeutics (RLMD), the 52-week high is $7.22, which is 112.44% from the current price. The 52-week low is $1.88, the current price is 80.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Relmada Therapeutics (RLMD) a growth stock?

Relmada Therapeutics (RLMD) has shown an average price growth of 0.41% over the past three years. It has received a score of 24 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Relmada Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Relmada Therapeutics (RLMD) stock price performance year to date (YTD)?

As of the latest data, Relmada Therapeutics (RLMD) has a year-to-date price change of -22.2%. Over the past month, the stock has experienced a price change of 24.09%. Over the last three months, the change has been 13.71%. Over the past six months, the figure is -31.17%.

help

Is Relmada Therapeutics (RLMD) a profitable company?

Relmada Therapeutics (RLMD) has a net income of -$98.79M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$103.7M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Relmada Therapeutics (RLMD)?

Relmada Therapeutics (RLMD) has a market capitalization of $98.67M. The average daily trading volume is 167.67K, indicating the stock's liquidity and investor engagement.